

NEONATAL West of Scotland Drug Monographs

Parenteral Routes

Neonatal

Palivizumab

FORM Vial containing 50 mg in 0.5 ml
Vial containing 100 mg in 1 ml

INDICATION Passive prophylaxis of respiratory syncytial virus (RSV) to neonates in clinical risk groups as defined by annual JCVI/Public Health report (published in the Green Book).
This is regardless of maternal RSV vaccination status.

DOSE RANGE

AGE	DOSE	FREQUENCY	ROUTE
Birth – 6 months	15 mg/kg (rounded up to nearest 5 mg)	Once monthly for up to five doses during RSV season (usually October to February). If being discharged during RSV season the first dose is given prior to discharge, ideally 24-48 hours prior.	IM

Administration	Palivizumab is available in a ready-to-use formulation with no further dilution required. Dose (ml) = 0.15 × weight (kg). Administered intramuscularly, preferably in the anterolateral aspect of the thigh. The gluteal muscle should not be used routinely as an injection site because of the risk of damage to the sciatic nerve. The injection should be given using standard aseptic technique Injection doses over 100 mg (1 ml) should be given as a divided dose.
-----------------------	--

FURTHER INFORMATION Infants should be offered palivizumab regardless of whether the mother was vaccinated during the pregnancy

STORAGE Store in a refrigerator and protect from light. Do not freeze.

LICENSED STATUS Licensed in all ages

APPLICABLE POLICIES West of Scotland Immunisation Guideline
Green Book Chapter 27a: Respiratory syncytial virus
Consult local policy if applicable

NEONATAL West of Scotland Drug Monographs

Parenteral Routes

Document Number:	002	Supersedes:	001
Prepared By/Checked By	Andrew Stockton/Maria Tracey	Final Approval By	WoS Neonatal Pharmacist Group
Date Prepared	August 2024	Review Date	August 2027

Administer reconstituted solutions immediately.
All vials, ampoules and infusion bags are for single use only unless otherwise stated.

Dose may vary depending on indication, age, renal function, hepatic function, and concomitant medications.
This monograph should be used in conjunction with the terms of reference document prepared by the West of Scotland Pharmacist Network. Information is correct at the time of publication and as per local practice agreement.
For further advice please contact your clinical pharmacist or pharmacy department
